| ［1］ |
Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation⁃associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease［J］. Arthritis Rheum, 2009,60（7）:2193⁃2200. doi: 10.1002/art.24621.
|
| ［2］ |
Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment［J］. J Am Acad Dermatol, 2020,82（2）:283⁃296. doi: 10.1016/j.jaad.2019.05.105.
|
| ［3］ |
Nombel A, Fabien N, Coutant F. Dermatomyositis with anti⁃MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies［J］. Front Immunol, 2021,12:773352. doi: 10.3389/fimmu.2021.773352.
|
| ［4］ |
Liu Z, Wang Q, Shao L, et al. The seborrheic dermatitis⁃distributed dermatomyositis: a facial cutaneous lesions sign associated with positive anti⁃MDA5 antibody［J］. J Cosmet Dermatol, 2022,21（3）:1309⁃1311. doi: 10.1111/jocd.14204.
|
| ［5］ |
Cabezas⁃Rodríguez I, Morante⁃Bolado I, Brandy⁃García A, et al. Anti⁃MDA5 dermatomyositis mimicking psoriatic arthritis［J］. Reumatol Clin （Engl Ed）, 2018,14（4）:224⁃226. doi: 10.1016/j.reuma.2016.10.010.
|
| ［6］ |
Zohar DN, Seluk L, Yonath H, et al. Anti⁃MDA5 positive dermatomyositis associated with rapidly progressive interstitial lung disease and correlation between serum ferritin level and treatment response［J］. Mediterr J Rheumatol, 2020,31（1）:75⁃77. doi: 10.31138/mjr.31.1.75.
|
| ［7］ |
Peng QL, Zhang YM, Liang L, et al. A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis［J］. Clin Exp Immunol, 2020,199（3）:314⁃325. doi: 10.1111/cei.13404.
|
| ［8］ |
Sato S, Masui K, Nishina N, et al. Initial predictors of poor survival in myositis⁃associated interstitial lung disease: a multicentre cohort of 497 patients［J］. Rheumatology （Oxford）, 2018,57（7）:1212⁃1221. doi: 10.1093/rheumatology/key060.
|
| ［9］ |
Nagashima T, Kamata Y, Iwamoto M, et al. Liver dysfunction in anti⁃melanoma differentiation⁃associated gene 5 antibody⁃positive patients with dermatomyositis［J］. Rheumatol Int, 2019,39（5）:901⁃909. doi: 10.1007/s00296⁃019⁃04255⁃2.
|
| ［10］ |
Yamasaki Y, Kobayashi N, Akioka S, et al. Clinical impact of myositis⁃specific autoantibodies on long⁃term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study［J］. Rheumatology （Oxford）, 2021,60（10）:4821⁃4831. doi: 10. 1093/rheumatology/keab108.
|
| ［11］ |
Labrador⁃Horrillo M, Martinez MA, Selva⁃O′Callaghan A, et al. Anti⁃MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis［J］. J Immunol Res, 2014,2014:290797. doi: 10.1155/2014/290797.
|
| ［12］ |
Sato S, Murakami A, Kuwajima A, et al. Clinical utility of an enzyme⁃linked immunosorbent assay for detecting anti⁃melanoma differentiation⁃associated gene 5 autoantibodies［J］. PLoS One, 2016,11（4）:e0154285. doi: 10.1371/journal.pone.015 4285.
|
| ［13］ |
Nakashima R, Mimori T. Anti⁃MDA5 （melanoma differentiation⁃associated gene 5） antibody and dermatomyositis with rapidly progressive interstitial pneumonia［J］. Nihon Rinsho Meneki Gakkai Kaishi, 2013,36（2）:71⁃76. doi: 10.2177/jsci.36.71.
|
| ［14］ |
Matsuda KM, Yoshizaki A, Kuzumi A, et al. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti⁃melanoma differentiation⁃associated gene 5 antibody⁃positive dermatomyositis［J］. J Dermatol, 2020,47（5）:483⁃489. doi: 10.1111/1346⁃8138.15274.
|
| ［15］ |
Kahn JS, Deverapalli SC, Rosmarin DM. JAK⁃STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis［J］. Int J Dermatol, 2018,57（8）:1007⁃1014. doi: 10.1111/ijd.14064.
|
| ［16］ |
Wendel S, Venhoff N, Frye BC, et al. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus⁃Kinase inhibitor tofacitinib ⁃ a report of two cases［J］. J Autoimmun, 2019,100:131⁃136. doi: 10.1016/j.jaut.2019.03.003.
|
| ［17］ |
Le Voyer T, Gitiaux C, Authier FJ, et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study［J］. Rheumatology （Oxford）, 2021,60（12）:5801⁃5808. doi: 10.1093/rheumatology/keab116.
|
| ［18］ |
Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis⁃associated interstitial lung disease［J］. N Engl J Med, 2019,381（3）:291⁃293. doi: 10.1056/NEJMc1900045.
|
| ［19］ |
Winters JL. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines［J］. Hematology Am Soc Hematol Educ Program, 2012,2012:7⁃12. doi: 10.1182/asheducation⁃2012.1.7.
|
| ［20］ |
Takahashi R, Yoshida T, Morimoto K, et al. Successful treatment of anti⁃MDA5 antibody⁃positive dermatomyositis⁃associated rapidly progressive⁃interstitial lung disease by plasma exchange: two case reports［J］. Clin Med Insights Case Rep, 2021,14:1179547 6211036322. doi: 10.1177/11795476211036322.
|
| ［21］ |
Endo Y, Koga T, Suzuki T, et al. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti⁃MDA5 antibody⁃positive dermatomyositis: a case report［J］. Medicine （Baltimore）, 2018,97（15）:e0436. doi: 10.1097/MD.00 00000000010436.
|
| ［22］ |
Kagawa H, Tsujino K, Yamamoto Y, et al. Acute lung injury after plasma exchange in a patient with anti⁃MDA5 antibody⁃positive, rapidly progressive, interstitial lung disease：a case report［J］. Respir Med Case Rep, 2020,29:101016. doi: 10.1016/j.rmcr. 2020.101016.
|
| ［23］ |
Scirocco C, Gubbiotti A, Sebastiani A, et al. Rituximab in antimelanoma differentiation⁃associated protein⁃5 dermato⁃myositis with interstitial lung disease［J］. Case Rep Rheumatol, 2020,2020:8145790. doi: 10.1155/2020/8145790.
|
| ［24］ |
Mao MM, Xia S, Guo BP, et al. Ultra⁃low dose rituximab as add⁃on therapy in anti⁃MDA5⁃positive patients with polymyositis /dermatomyositis associated ILD［J］. Respir Med, 2020,172:105983. doi: 10.1016/j.rmed.2020.105983.
|
| ［25］ |
Abraham D, Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis［J］. Arthritis Res Ther, 2007,9 Suppl 2（Suppl 2）:S2. doi: 10.1186/ar2186.
|
| ［26］ |
Min HK, Kim HR, Lee SH, et al. Refractory digital ulcers treated by botulinum toxin and endothelin receptor⁃1 antagonist in anti⁃MDA5⁃antibody⁃positive dermatomyositis［J］. J Clin Neurol, 2020,16（1）:160⁃162. doi: 10.3988/jcn.2020.16.1.160.
|
| ［27］ |
Collantes⁃Rodríguez C, Jiménez⁃Gallo D, Ossorio⁃García L, et al. Image gallery: cutaneous ulcers in anti⁃MDA5 dermatomyositis successfully treated with sildenafil［J］. Br J Dermatol, 2020,182（1）:e1. doi: 10.1111/bjd.18376.
|
| ［28］ |
Leclair V, Labirua⁃Iturburu A, Lundberg IE. Successful lung transplantation in a case of rapidly progressive interstitial lung disease associated with antimelanoma differentiation⁃associated gene 5 antibodies［J］. J Rheumatol, 2018,45（4）:581⁃583. doi: 10.3899/jrheum.171047.
|
| ［29］ |
Deitchman AR, Kalchiem⁃Dekel O, Todd N, et al. Rapidly progressive interstitial lung disease due to anti⁃melanoma differentiation associated protein⁃5 requiring a bilateral lung transplant, and complicated by kennel cough［J］. Respir Med Case Rep, 2019,28:100886. doi: 10.1016/j.rmcr.2019.100886.
|
